Humanization of Tumor Stroma by Tissue Engineering as a Tool to Improve Squamous Cell Carcinoma Xenograft.
Animals
Cancer-Associated Fibroblasts
/ pathology
Carcinoma, Squamous Cell
/ pathology
Cell Line
Cell Line, Tumor
Epithelial Cells
/ pathology
Female
Fibroblasts
/ pathology
Heterografts
/ pathology
Humans
Mice
Neoplasm Transplantation
/ pathology
Neovascularization, Pathologic
/ pathology
Stromal Cells
/ pathology
Tissue Engineering
/ methods
Transplantation, Heterologous
/ methods
CAF
SCC
stroma
tissue engineering
tumor
xenografts
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Mar 2020
12 Mar 2020
Historique:
received:
28
01
2020
revised:
26
02
2020
accepted:
09
03
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
2
12
2020
Statut:
epublish
Résumé
The role of stroma is fundamental in the development and behavior of epithelial tumors. In this regard, limited growth of squamous cell carcinomas (SCC) or cell-lines derived from them has been achieved in immunodeficient mice. Moreover, lack of faithful recapitulation of the original human neoplasia complexity is often observed in xenografted tumors. Here, we used tissue engineering techniques to recreate a humanized tumor stroma for SCCs grafted in host mice, by combining CAF (cancer associated fibroblasts)-like cells with a biocompatible scaffold. The stroma was either co-injected with epithelial cell lines derived from aggressive SCC or implanted 15 days before the injection of the tumoral cells, to allow its vascularization and maturation. None of the mice injected with the cell lines without stroma were able to develop a SCC. In contrast, tumors were able to grow when SCC cells were injected into previously established humanized stroma. Histologically, all of the regenerated tumors were moderately differentiated SCC with a well-developed stroma, resembling that found in the original human neoplasm. Persistence of human stromal cells was also confirmed by immunohistochemistry. In summary, we provide a proof of concept that humanized tumor stroma, generated by tissue engineering, can facilitate the development of epithelial tumors in immunodeficient mice.
Identifiants
pubmed: 32178458
pii: ijms21061951
doi: 10.3390/ijms21061951
pmc: PMC7139348
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Comunidad de Madrid
ID : B2017/BMD-3692
Organisme : Instituto de Salud Carlos III
ID : PI17/01747
Organisme : Ministerio de Ciencia e Innovación
ID : SAF2017-86810-R
Organisme : DEBRA International
ID : HEALTH-F2-2011-261392
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Metastasis Rev. 1991 Oct;10(3):263-74
pubmed: 1722435
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
Sci Transl Med. 2018 Aug 22;10(455):
pubmed: 30135250
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Orphanet J Rare Dis. 2019 Jul 24;14(1):183
pubmed: 31340837
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Burns. 1998 Nov;24(7):621-30
pubmed: 9882060
EJNMMI Radiopharm Chem. 2019 Jul 25;4(1):16
pubmed: 31659499
J Invest Dermatol. 2019 Jul;139(7):1497-1505.e5
pubmed: 30684555
J Cell Sci. 2009 Jun 1;122(Pt 11):1788-99
pubmed: 19435799
J Clin Med. 2018 Mar 02;7(3):
pubmed: 29498669
J Natl Cancer Inst. 2015 Oct 16;108(1):
pubmed: 26476432
Oncol Rep. 2015 Nov;34(5):2699-705
pubmed: 26352907
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Matrix Biol. 2017 Nov;63:1-10
pubmed: 28126522
J Hematol Oncol. 2020 Jan 7;13(1):4
pubmed: 31910904
Cancer Res. 2002 Jun 15;62(12):3402-7
pubmed: 12067982
J Pathol. 2009 Dec;219(4):455-62
pubmed: 19824060
Cancer Res. 2018 Oct 15;78(20):5958-5969
pubmed: 30154149
Br J Dermatol. 2019 Sep;181(3):512-522
pubmed: 30693469
Cancer Res. 2007 May 1;67(9):4244-53
pubmed: 17483336
Nat Commun. 2018 Sep 10;9(1):3667
pubmed: 30202019
J Natl Cancer Inst. 1992 Jun 17;84(12):951-7
pubmed: 1378502
Clin Cancer Res. 2019 Jun 1;25(11):3384-3391
pubmed: 30846478
Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2
pubmed: 26083672
Chin Clin Oncol. 2019 Apr;8(2):17
pubmed: 30943729
Cancer Res. 2016 Feb 15;76(4):940-51
pubmed: 26676755
J Thorac Oncol. 2011 Jan;6(1):209-17
pubmed: 21107292
Hum Gene Ther. 2002 May 20;13(8):959-68
pubmed: 12031128
Front Oncol. 2019 Jul 31;9:688
pubmed: 31417869
J Invest Dermatol. 2012 Feb;132(2):284-90
pubmed: 21975825
Cancer Lett. 2014 Mar 1;344(1):1-12
pubmed: 24157811
FASEB J. 2001 Jul;15(9):1529-38
pubmed: 11427484
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71
pubmed: 15051869
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739489
J Pathol. 2003 Jul;200(4):429-47
pubmed: 12845611
J Invest Dermatol. 2016 Feb;136(2):e13-e17
pubmed: 26802242
Cancer Res. 2012 Jul 15;72(14):3522-34
pubmed: 22564523
Gynecol Oncol. 2020 Jan;156(1):222-232
pubmed: 31818495
Methods Mol Biol. 2011;731:151-9
pubmed: 21516406
Oncoimmunology. 2019 Mar 30;8(6):e1586042
pubmed: 31069153